Bayer AG (BAYRY) Lifted to "Hold" at Zacks Investment Research


According to Zacks, "Bayer's first-quarter results were mixed with the company beating on earnings, but missing revenue estimate. Nevertheless, we remain positive on the newly launched pharmaceutical products that drove revenues in the first quarter.



from Biotech News